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Subjects treated with any drug-eluting stent (DES) approved and available in the United
States at the time of study enrollment were eligible to be enrolled in the DAPT Study. While patients were not randomized to stent types, in adjusted analysis there was heterogeneity in the relative reduction in MACCE (major adverse cardiovascular and cerebrovascular events; a composite endpoint of death, MI or stroke) according to stent type, (1) and a large treatment benefit for continued therapy was observed among the subset of patients treated with paclitaxeleluting stents (N=2666 randomized). (6) To determine whether the results of the DAPT Study were generalizable to EES we evaluated the benefits and risks of treatment with thienopyridine plus aspirin for 30 vs. 12 months in the large subset of patients (11308 enrolled, 4703 randomized).
METHODS
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Design
The DAPT Study was a double-blind, international, multi-center, randomized placebocontrolled trial, designed (7) to compare 30 versus 12 months of aspirin plus thienopyridine therapy (clopidogrel or prasugrel) after coronary stenting with either DES or BMS (ClinicalTrials.gov # NCT00977938). Randomization was stratified by DES/BMS, hospital site, subject complexity and thienopyridine drug type. The results comparing randomized treatments among DES(1) and BMS-treated(2) cohorts on ischemic and bleeding endpoints, as well as comparing BMS-vs. DES-treated patients(8) on these endpoints, have been reported. The institutional review board at each participating institution approved the study and each participant provided written, informed consent.
The primary study analysis within all randomized DES-treated patients compared randomized treatments with respect to the primary effectiveness end points of stent thrombosis and MACCE from 12 to 30 months post-procedure, and the primary safety endpoint of moderate or severe bleeding from 12 to 30 months post-procedure.(1) DES types included EES (Xience, Abbott Vascular; PROMUS, Boston Scientific), sirolimus-eluting (SES; Cypher, Cordis), zotarolimus-eluting (ZES; Endeavor, Medtronic), and paclitaxel-eluting (PES; TAXUS, Boston Scientific). While stent type among various DES was not randomized, assessments of randomized treatment-by-DES type interactions on stent thrombosis and MACCE were prespecified to determine whether the randomized treatment effect was consistent across DES types. While randomized treatment effect on stent thrombosis did not vary by stent type (interaction p=0.76), variation in treatment effect on MACCE was observed (interaction p=0.048).
(1) The current analysis was performed among randomized subjects treated only with EES, to determine the effects of treatment, particularly on those end points that could be M A N U S C R I P T A C C E P T E D 
Study Population and Procedures
Adult candidates for thienopyridine plus aspirin therapy who were treated with Food and Drug Administration (FDA)-approved coronary stents were enrolled within 3 days of stent placement. All patients received open-label aspirin plus thienopyridine for 12 months after coronary stenting, and at month 12, patients who had tolerated DAPT without a MACCE, repeat revascularization, or moderate or severe bleeding event and who had been adherent to thienopyridine therapy (defined as having taken 80 to 120% of the drug without an interruption of longer than 14 days) continued aspirin and were randomized to either continued thienopyridine or to placebo for a further18 months. event. Cancer-related death was adjudicated as any death that was possibly, probably, or definitely related to a malignancy or complications from treatments specifically administered for the malignancy. Causes of death were not mutually exclusive, i.e. a patient could have both a bleeding-related and a cancer-related death.
A central data safety monitoring board and an independent biostatistician reviewed unblinded data from all subjects at regular intervals.
Statistical Analysis
All analyses were performed on the subset of all randomized EES-treated patients, according to the intention-to-treat principle. Analysis of the interaction of stent type and treatment assignment (duration of antiplatelet therapy) on the outcomes of stent thrombosis, MACCE and GUSTO severe or moderate bleeding, was prespecified, as described above. The Cox proportion hazards assumption was met for these endpoints for the primary DES cohort and for the EES-treated subset. All other within subset analyses (i.e. comparing randomized treatment arms within EES-treated subjects) were not prespecified.
Kaplan-Meier estimates of endpoint events were calculated for each treatment group. For the outcomes of stent thrombosis, MACCE, death, MI and GUSTO severe or moderate bleeding, hazard ratios and 95% confidence intervals (CIs) were adjusted for baseline characteristics; adjusted Cox proportional hazard regression p values were used to compare the treatment difference and to assess randomized treatment by DES type interaction effects. For all other outcomes, hazard ratios and 95% CIs were stratified by randomization strata; Kaplan-Meier estimates were compared between treatment groups using log-rank p value stratified by randomization strata. 
RESULTS
Study Population
Of 25,682 patients enrolled into the DAPT Study, 11,308 received an EES; of 11,648 randomized patients, 9961 received a DES at the index procedure, with the following stent types: thienopyridine or placebo, respectively. Within EES-treated patients, there were no significant differences between randomized groups on baseline characteristics except that those randomized to continued thienopyridine were slightly older. (Table 1) As expected due to lack of randomization to stent type, EES-treated subjects differed from patients treated with other DES. EES patients were slightly older (mean age 62.3 vs 61.2 years), had a lower body mass index (30.3 vs 30.8 kg/m 2 ), were more likely to be treated with clopidogrel (84.4% vs. 48.2%) and less likely to receive prasugrel (15.6% vs. 51.8%), and were more likely to have had a prior history of cancer (all p<0.001, Online Appendix Table 2 ).
Reduction in stent thrombosis (interaction p=0.76) and MI (interaction p=0.11) with continued thienopyridine therapy vs. placebo was consistent among all DES after adjustment for
differences in patient characteristics and type of thienopyridine, as was the increase in bleeding (interaction p=0.46) and mortality (interaction p=0.17), while there was variation in the magnitude of risk reduction in MACCE across stent types (interaction p=0.048)(1).
Effect of Continued Thienopyridine Therapy Among EES-Treated Patients
Amongst EES-treated patients randomized to continued thienopyridine or placebo, Figure 2D ).
Mortality
During the randomized treatment period (12-30 months after enrollment), all-cause mortality was 2.2% vs. 1.1% in the continued thienopyridine arm vs placebo (HR 1.80, 95% CI The most common non-cardiovascular condition related to mortality was cancer (N=18 vs. 4, p=0.002); few of these cancers-related deaths were associated with bleeding (3 of 18 in the continued thienopyridine arm, 0 of 4 in the placebo arm, Table 3 ).
Death related to cancer and also related to bleeding occurred in 3 of 18 total cancer-related was not randomized and individual stent type subsets were not prespecified nor powered to compare treatment effect, analysis of the consistency of treatment effect was prespecified.
In this context, the following observations were made. First, continued thienopyridine plus aspirin beyond 1 year (versus aspirin alone) significantly reduced the incidence of stent thrombosis and MI following EES treatment. Second, although heterogeneity in treatment duration benefit for reduction in the composite endpoint of MACCE was present for EES, this observation appears to be in large part driven by a greater increase in mortality with continued thienopyridine therapy while the beneficial effect on MI was consistent across stent types. 
Study Limitations
Specific limitations that apply to comparisons of absolute event rates across DES types in this study include the post hoc nature of the analysis, lack of randomization to DES type, demographic differences between DES treatment groups and smaller stent group sample sizes (lack of power), and the limitations of multiple comparisons. Additionally, despite the relatively large EES group size, tests of interaction on randomized treatment effect between stent groups remain underpowered. Finally, false positive related to multiple testing may also be present within these subgroup analyses.
Conclusions
Continued thienopyridine therapy beyond 1 year following EES treatment is associated with significant reductions in risk of stent thrombosis or MI and an increased risk of bleeding.
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CLINICAL PERSPECTIVES
What is Known?
Recent randomized trials and meta-analysis suggest that everolimus-eluting stents (EES), the most commonly used stent type in the Dual Antiplatelet Therapy (DAPT) Study, are associated with lower rates of stent thrombosis compared with paclitaxel eluting stents.
What is New?
In a post hoc subset analysis of the DAPT Study in patients treated with EES, continued thienopyridine plus placebo beyond one year was associated with reduced rates of stent thrombosis and myocardial infarction, and increased rates of bleeding.
What is Next?
This study contributes to the growing body of evidence regarding prevention of stent thrombosis and myocardial infarction after coronary stenting with continued dual antiplatelet therapy, as well as the risks of increased bleeding. Additional research is needed to further individualize therapy to optimize patient selection for continued thienopyridine therapy. ‡A total of 3043 lesions were treated in subjects randomized to continued thienopyridine and 3007 in subjects randomized to placebo. 
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